NuCana PLC Cash Flow Conversion Efficiency
NuCana PLC cash flow conversion efficiency. Based on the latest financial reports, NuCana PLC (NCNA) has a cash flow conversion efficiency ratio of -0.096x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.93 Million) by net assets ($20.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of NuCana PLC (2014–2025)
Cash flow conversion efficiency of NuCana PLC from 2014 to 2025. This chart illustrates how NuCana PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NuCana PLC share price for real-time trading data and today's change.
NuCana PLC Cash Flow Conversion Ratio Explained
NuCana PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
NuCana PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NuCana PLC ranked by their cash flow conversion efficiency. Also see NuCana PLC market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Visible Gold Mines Inc
V:VGD
|
-0.072x |
|
Karma Energy Limited
NSE:KARMAENG
|
0.027x |
|
Metal Bank Ltd
AU:MBK
|
-0.024x |
|
Ecora Resources PLC
LSE:ECOR
|
0.005x |
|
Forterra PLC
LSE:FORT
|
0.109x |
|
Rare Earth Magnesium Technology Group Holdings Limited
STU:GPS
|
0.016x |
|
Boutique Newcity Public Company Limited
BK:BTNC
|
0.008x |
|
Duksung Co Ltd
KO:004835
|
0.037x |
Annual Cash Flow Conversion Efficiency for NuCana PLC (2014–2025)
The table below shows the annual cash flow conversion efficiency of NuCana PLC from 2014 to 2025. Review cash generation quality of NuCana PLC to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $24.33 Million | $-7.47 Million | -0.307x | +90.44% |
| 2024-12-31 | $5.95 Million | $-19.12 Million | -3.211x | -80.80% |
| 2023-12-31 | $14.89 Million | $-26.44 Million | -1.776x | -195.27% |
| 2022-12-31 | $38.50 Million | $-23.16 Million | -0.601x | -65.49% |
| 2021-12-31 | $65.55 Million | $-23.82 Million | -0.363x | -66.83% |
| 2020-12-31 | $99.23 Million | $-21.62 Million | -0.218x | +41.93% |
| 2019-12-31 | $63.52 Million | $-23.83 Million | -0.375x | -150.44% |
| 2018-12-31 | $81.59 Million | $-12.22 Million | -0.150x | -60.72% |
| 2017-12-31 | $93.42 Million | $-8.71 Million | -0.093x | +74.60% |
| 2016-12-31 | $25.24 Million | $-9.26 Million | -0.367x | -146.16% |
| 2015-12-31 | $29.96 Million | $-4.47 Million | -0.149x | +99.90% |
| 2014-12-31 | $34.51K | $-5.25 Million | -151.998x | -- |
About NuCana PLC
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metab… Read more